Molecular Results Mapping: Frequently Asked Questions Copied

01/08/2026FAQPhysician, Clinical, Admin, Billing

Last year, we introduced biomarker results integration, where certain biomarker values could easily be added to the Problems List from the Molecular Results sub-tab in iKnowMed Generation 2.

Through a partnership with Genospace, we’re helping capture data faster and reducing the need for manual data entry for additional disease states. Additionally, you’ll now be able to add results to the problems list through Unified Sign Queue.

This functionality is currently available to US Oncology Network practices, that also have agreements with both the Sara Cannon Research Institute and Genospace. If you have questions about access to this functionality, please contact your Ontada Technology Account Manager.

Do I have to have Clear Value Plus enabled for this functionality?

No, you do not need Clear Value Plus enabled to use this functionality. This functionality is available in iKnowMed. If your practice has Clear Value Plus enabled in iKnowMed, these results will seamlessly appear in the patient details section in the left column of the window.

What best practices are recommended to get the most out of this functionality?

As a best practice, we recommend documenting a principal diagnosis in the problems list. Additionally, please mark any problems which may be duplicated in the Problem List as inactive. If a Problem is listed more than once with the same name, it can cause an issue saving to the Problem List until one of the problems is marked as inactive.

I’d like to learn more about using the Problems List as recommended, what resources are available for me?

The iKnowMed Help Menu has training and step-by-step instructions on using this functionality. To learn more visit the following link: Problems Tab

I don’t use the Unified Sign Queue in iKnowMed, will I be able to add to the problems list from Lab queue?

No, molecular results mapping will not be available in the Lab Queue. You’ll still be able to add results to the problems list from the Molecular Results sub-tab.

My practice doesn’t currently use Unified Sign Queue. How do we enable it?

A user with the Administrator role in iKnowMed would enable the Practice Preference: Admin > Practice Preferences > Unified Sign Queue. Once enabled, users at your practice can enable their individual settings by going to: Permission > Worklist Queues > Unified Sign Queue.

I’d like to learn more about using the Unified Sign Queue as recommended, what resources are available for me?

The iKnowMed Help Menu has training and step-by-step instructions on using this functionality. To learn more visit the following link: Unified Sign Queue

What diseases are supported with this functionality?

  • Anal Cancer
  • Bile Duct Cancer
  • Bladder Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Esophageal Cancer
  • Fallopian Tube
  • Gallbladder Cancer
  • Gastric Cancer
  • Hypopharyngeal (Head & Neck) Cancer
  • Kidney (Renal) Cancer
  • Laryngeal (Head & Neck) Cancer
  • Liver Cancer
  • Melanoma
  • Neuroendocrine Cancer
  • NSCLC (Non-Small Cell Lung Carcinoma)
  • Oropharyngeal Cancer
  • Ovarian/Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Rectal Cancer
  • SCLC (Small Cell Lung Cancer)
  • Uterine Cancer

Which vendors are supported with this functionality?

The following vendors are supported:

  • Caris Life Sciences
  • Foundation Medicine
  • Guardant Health
  • Tempus

Which result groups and associated results have been automatically mapped for review?

The following results groups and associated results have been automatically selected for review:

  • Tier 1 Level A variants with FDA approved therapeutic associations (companion diagnostic biomarkers).
    • Example: BRAF V600E result selects V600E mutation
    • Example: C-KIT W557R result selects Detected in Melanoma
  • Tier 1 variants with strong clinical evidence denoted as known/likely pathogenic variants by testing vendor that do not have any therapeutic associations.
    • Example: KRAS G12D result selects Other KRAS mutation or Other non-actionable finding depending on the diagnosis.
  • Differentiate Wild-type/Negative versus Not Tested/Unknown depending on specific vendor and test used together with absence of relevant alterations, where relevant alterations are driven by ‘Positive’ biomarker definition.
    • Example: BRAF Wild type in Melanoma is selected if results show absence of any mutation and fusion, and if the test used tests for both BRAF mutations and fusions.
  • Example: BRAF Unknown in Melanoma is selected if results show absence of any mutation and fusion, yet the test used does not test for both BRAF mutations and fusions.
  • IHC and genomic signatures such as PD-L1, TMB (tissue-based results only), MSI (excluding MSI-H “Not Detected” by blood-based tests), MMR, and Homologous Recombination status.
    • Example: Tissue-Based MSI-H selects “High”
    • Example: Blood-Based MSI-H “Not Detected” does not auto-select any value by design.

Are there any result groups not included in this integration?

This initial integration does not include:

  • EGFR in Colon and Rectal cancers: Only “Negative” will be selected by the Genospace integration given the significance of pertinent negatives and therapeutic associations in these cancers. Otherwise, EGFR is out-of-scope for these cancers.
  • HER-2/neu IHC and ISH results, as well as ER and PR IHC results, are excluded and will not surface in this workflow given lack of coverage across most testing vendors.
    Lynch Syndrome results for Uterine and Colon cancers.

Will other result types be added to this functionality for example HER2 IHC and germline BRCA results?

Yes, we plan to release additional content enhancements as we work to integrate with other reference laboratories.

Why do I sometimes see a message displayed that results are still processing when I see the report and tabular data?

iKnowMed and our Genospace partners receive lab results from vendors differently. iKnowMed receives results from lab vendors throughout the day when the results are signed. Lab vendors transmit results to our Genospace partners to process for Problem List additions daily. Some lab vendors send at the same time daily, and some vendors send when a batch threshold is met. Once the batch is received, Genospace processes the result in 30 minutes or less.

If a Problem has not been documented on the Problem list prior to when the molecular results are received, this would also affect the ability to use the Add to Problem feature for the molecular testing results.

Why is there an increased number of errors in my Manage Errors interface queue for patient matching?

This is a routine part of our auto match process to ensure your practice appropriately reconicles with the correct patient in your system.

Errors for Molecular Results (Pdf + Tabular Data) will continue to display in the same format as today.    The new messages for patient manual match for biomarker inference mapping will display the error: “Patient Manual Match Error- GP”.

What should I do if I see the error “Patient Match Error- GP”?

For any instance of this error, search by patient name to ensure all open errors for that patient are resolved. Follow your existing process of resolving and accepting the patient record. In near real time, any pending records will resolve and flow into your system.

Periodically, a patient record may still appear in this queue if it does not meet all criteria for an automatic match. Continue to follow your existing process for managing patient matching within the Interface queue.